European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases

Dutch InteRNA Technologies is collaborating with the Neuroallianz Consortium, an academic-industry partnership with Belgium-based UCB and the Rheinische Friedrich-Wilhelms-University of Bonn in Germany, to develop and study microRNA therapeutics in neurodegenerative diseases. Under the agreement, InteRNA will screen assays to identify and validate the biological role of individual miRNAs and novel therapeutic targets for neurodegenerative diseases. InteRNA is building a pipeline of miRNA drug candidates for cancer, but it is also looking into other miRNA drug candidates and their mode of action for other disease indications. Release